Compare QUBT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | ANIP |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2019 | 1999 |
| Metric | QUBT | ANIP |
|---|---|---|
| Price | $11.29 | $82.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $17.50 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 18.6M | 296.7K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 84.93 | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | $682,000.00 | ★ $206,547,000.00 |
| Revenue This Year | $3,210.56 | $21.01 |
| Revenue Next Year | $51.26 | $17.59 |
| P/E Ratio | ★ N/A | $63.96 |
| Revenue Growth | ★ 82.84 | 2.47 |
| 52 Week Low | $6.18 | $56.71 |
| 52 Week High | $25.84 | $99.50 |
| Indicator | QUBT | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 57.17 |
| Support Level | $10.12 | $77.32 |
| Resistance Level | $13.14 | $83.58 |
| Average True Range (ATR) | 1.04 | 3.19 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 40.40 | 54.55 |
Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.